Abstracts

Prevalence of Cryptococcal Antigen Positivity among AIDS Patients United States from 1986-2012

Background: Cryptococcal meningitis (CM) is the most common cause of AIDS-related mortality in sub-Saharan Africa. CM accounts for between 33% and 63% of all adult meningitis within that region and is responsible for over 500,000 deaths annually; more AIDS-related deaths than tuberculosis. In sub-Saharan Africa, the WHO recommends routinely screening AIDS patients with a CD4…

High Prevalence of Undiagnosed Cryptococcus at HIV Diagnosis across the CD4 Spectrum in Durban

Background: Early detection and treatment of cryptococcal antigen (CrAg) may decrease morbidity and mortality from cryptococcal meningitis. Based on World Health Organization guidelines, South Africa recommends screening all HIV-infected people with CD4 100/mm3 had an estimated CrAg prevalence of 9.9% (95% CI 7.2-12.6%), which was not significantly difference from those with CD4 ≤100/mm3 (8.7%; 95%…

Cryptococcal Antigenemia in Severely Immunocompromised HIV Patients in Rural Tanzania

Background: Cryptococcal meningitis is a leading cause of death in people living with HIV/AIDS in sub-Saharan Africa. To decrease cryptococcosis, WHO recommends pre-antiretroviral (ART) targeted cryptococcal antigen (CrAg) screening for persons with CD4 < 100 cells/μL. Aiming to explore the potential impact of this strategy in Tanzania, we assessed the prevalence, natural course, and outcome…

Serum Biomarkers Following Induction Therapy for Cryptococcal Meningitis Predict Survival

Background: In the Cryptococcal Optimal ART Timing (COAT) trial, early ART initiation (7-13 days) after cryptococcal meningitis (CM) was associated with higher mortality compared with deferred (5 weeks) ART initiation. A significant proportion of deaths (70%, 49/70) occurred after completion of 14 days of amphotericin induction therapy. We hypothesized that serum biomarkers may enable risk…

Monocyte dysfunction is associated with 14-day mortality in cryptococcal meninigits

Background: Cryptococcal meningitis (CM) remains a significant cause of death amongst individuals with HIV-1 infection. Immune correlates of protection are lacking. Animal and in vitro studies suggest macrophage and monocyte activation plays a key role in determining outcome from infection. This study examines the relationship between peripheral blood monocyte activation and clinical outcome in patients…

Increased Arterial Inflammation Relates to High-Risk Coronary Plaque Morphology in HIV+ Patients*

Background: CVD is increased in HIV, but specific mechanisms remain unknown. Among HIV+ patients, independent studies demonstrate increased arterial inflammation (by 18F-FDG-PET) and increased high risk morphology (HRM) coronary atherosclerotic plaque (by coronary CT angiography, CTA). However, the critical interrelationship between these features in HIV+ patients has not been assessed. We hypothesized that arterial inflammation…

Arterial Inflammation in HIV as Measured by FDG-PET/CT Is Associated With Splenic Activity

Background: HIV-infected individuals have increased arterial inflammation and higher risk of cardiovascular disease (CVD), likely related to chronic monocyte/macrophage (MΦ) activation. Arterial inflammation as assessed by 18fluorodeoxyglucose (FDG) PET/CT correlates with MΦ activity and is predictive of CVD risk. Since MΦ that participate in atherosclerosis originate in the bone marrow and transiently reside in the…

Replicative Senescence of Circulating Osteogenic Cells and Low BMD in Perinatally Infected Men

Background: We have previously demonstrated that men infected with HIV early in life have 6-19% lower volumetric bone mineral density (vBMD) markedly abnormal trabecular plate and cortical microarchitecture and decreased whole bone stiffness by High Resolution peripheral Quantitative CT (HRpQCT) of the radius and tibia. We hypothesize that early HIV infection is associated with accelerated…

High Dose Vitamin D and Calcium Attenuates Bone Loss With ART Initiation: Results From ACTG A5280

Background: Low bone mineral density (BMD) is common among HIV-infected persons, and the initiation of ART (particularly tenofovir-containing regimens) is associated with 2-5% loss in BMD. Vitamin D deficiency is common among HIV-infected and uninfected individuals; further, efavirenz decreases vitamin D levels. Vitamin D and calcium supplementation have well-described beneficial effects on bone health. Methodology:…

Rosuvastatin Improves Hip Bone Mineral Density But Worsens Insulin Resistance

Background: The effect of statin therapy on bone mineral density (BMD) in HIV-infected subjects on antiretroviral therapy (ART) is unknown. Also, there are conflicting reports on statin increasing the risk of diabetes in HIV-infected subjects. Methodology: The 96-week Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN in HIV (SATURN-HIV) trial is a randomized, doubleblind, placebo-controlled…